Search - tctmd.com

Displaying 281 - 300 of 552

Sort: Relevancy | Date

Omecamtiv Mecarbil--Is It More Effective in Low EFs and Is It Better Than Digoxin?

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Secubitirl-Valsartan Across the Spectrum of EFs

Presentation THT 2022

Secubitirl-Valsartan Across the Spectrum of EFs

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Vericiguat

Presenter: Javed Butler

February 01, 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

February 2022 News Roundup

News Opinion CV Team Dispatch

February 2022 News Roundup

February 01, 2022

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

January 21, 2022

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

News Opinion Fellow Talk

A Trainee’s Perspective on the First Genetically Engineered Pig-to-Human Cardiac Xenotransplantation

Corbin E. Goerlich, MD

January 13, 2022

With First-in-Human Porcine Heart Transplant, a New Chapter Begins

News Daily News

With First-in-Human Porcine Heart Transplant, a New Chapter Begins

Yael L. Maxwell

January 11, 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

News Daily News

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

December 14, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

GUIDE-HF: A Randomized Trial of Hemodynamic-Guided Management of Heart Failure – Outcomes According to Ejection Fraction

Presentation TCT 2021

GUIDE-HF: A Randomized Trial of Hemodynamic-Guided Management of Heart Failure – Outcomes According to Ejection Fraction

Presenter: Michael Zile

November 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.